AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

BioXcel Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

November 26, 2019 GMT

NEW HAVEN, Conn.--(BUSINESS WIRE)--Nov 26, 2019--

BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the Piper Jaffray 31st Annual Healthcare Conference being held December 3 – 5, 2019 in New York City.

Presentation Details:
Event: Piper Jaffray 31st Annual Healthcare Conference
Date: Tuesday, December 3, 2019
Time: 11:50 a.m. – 12:10 p.m. ET

A live webcast of the presentation and the accompanying presentation materials that will be discussed will be accessible through the Investors section of the company’s website at www.bioxceltherapeutics.com. Following the conference, the webcast will be archived on the BioXcel Therapeutics, Inc. website for at least 30 days.

About BioXcel Therapeutics, Inc.:

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI’s drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI’s two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit www.bioxceltherapeutics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191126005246/en/

CONTACT: BioXcel Therapeutics, Inc.

www.bioxceltherapeutics.comInvestor Relations:

John Graziano

jgraziano@troutgroup.com

1.646.378.2942Media:

Julia Deutsch

jdeutsch@troutgroup.com

1.646.378.2967

KEYWORD: UNITED STATES NORTH AMERICA CONNECTICUT

INDUSTRY KEYWORD: ONCOLOGY HEALTH TECHNOLOGY SOFTWARE GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: BioXcel Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 11/26/2019 07:00 AM/DISC: 11/26/2019 07:01 AM

http://www.businesswire.com/news/home/20191126005246/en